Carbapenem-resistance in enterobacteriaceae, pseudomonas aeruginosa and acinetobacter baumannii;Carbapenem-Resistenz bei Enterobakterien, Pseudomonas aeruginosa und Acinetobacter baumannii

Deutsche Medizinische Wochenschrift

Volumn 140, Issue 3, 2015, Pages 172-176

  Mischnik, Alexander ^a   Kaase, Martin ^b   Lübbert, Christoph ^c   Seifert, Harald ^d,e   Kern, Winfried V ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e Deutsches Zentrum für Infektionsmedizin DZIF   (Germany)

Author keywords

carbapenemase; combination therapy; continuous application; resistance

Indexed keywords

CARBAPENEM; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; NONHUMAN; NOTE; PSEUDOMONAS AERUGINOSA; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; ENTEROBACTERIACEAE; HUMAN; MICROBIAL SENSITIVITY TEST;

ACINETOBACTER BAUMANNII; CARBAPENEMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 84923332482     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0041-100105     Document Type: Note

References (16)

1. Corvec S., Furustrand Tafin U. et al. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-beta-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother: 2013; 57 1421 1427
2. Falagas M. E., Lourida P., Poulikakos P. et al. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother: 2014; 58 654 663
3. Gonzalez-Padilla M., Torre-Cisneros J., Rivera-Espinar F. et al. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother: 2014; 10.1093/jac/dku432
4. Lefort A., Chau F., Lepeule R. et al. Activity of fosfomycin alone or combined with cefoxitin in vitro and in vivo in a murine model of urinary tract infection due to Escherichia coli harbouring CTX-M-15-type extended-spectrum beta-lactamase. Int J Antimicrob Agents: 2014; 43 366 369
5. MacLeod D. L., Velayudhan J., Kenney T. F. et al. Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa. Antimicrob Agents Chemother: 2012; 56 1529 1538
6. Mimoz O., Gregoire N., Poirel L. et al. Broad-spectrum beta-lactam antibiotics for treating experimental peritonitis in mice due to Klebsiella pneumoniae producing the carbapenemase OXA-48. Antimicrob Agents Chemother: 2012; 56 2759 2760
7. Nordmann P., Poirel L. Strategies for identification of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother: 2013; 68 487 489
8. Parker S., Lipman J., Koulenti D. et al. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents: 2013; 42 289 293
9. Paul M., Carmeli Y., Durante-Mangoni E. et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother: 2014; 69 2305 2309
10. Pea F., Viale P., Cojutti P. et al. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics / pharmacodynamics-based approach. Antimicrob Agents Chemother: 2012; 56 6343 6348
11. Peleg A. Y., Hooper D. C. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med: 2010; 362 1804 1813
12. Pogue J. M., Neelakanta A., Mynatt R. P. et al. Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the detroit medical center. Clin Infect Dis: 2014; 59 06 S388 393
13. Ramirez J., Dartois N., Gandjini H. et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother: 2013; 57 1756 1762
14. Robert Koch-Insitut Bericht des Nationalen Referenzzentrums für gramnegative Krankenhauserreger (1. Januar 2013 bis 31. Dezember 2013). Epidemiologisches Bulletin: 2014; 43 421 425
15. Stocker H., Kern W. V. [Colistin: renaissance of an old antibiotic?]. Internist: 2013; 54 936 944
16. Tasina E., Haidich A. B., Kokkali S. et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis: 2011; 11 834 844